Home Home Home Inbox Home Search

Event

Revefenacin, a Once-Daily, Long-Acting Muscarinic Antagonist for Nebulized Therapy of Chronic Obstructive Pulmonary Disease (COPD): Results of a 52-Week Safety and Tolerability Phase 3 Trial in Participants with Moderate to Very Severe COPD [Board No. 613]

Location: Board no. 613
Session Type: RAPiD: Rapid Abstract Poster Discussion Session
Monday
May
21
2:15 PM
4:15 PM
Home Home Home Inbox Home Search